

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Thrombosis	Integrin $\alpha_{IIb}\beta_3$; Src	A study in cell culture suggests that a fatty acid-modified peptide derived from integrin could be useful for treating thrombosis. In washed human platelets, the cell-permeable peptide (called RGT) dose-dependently inhibited platelet adhesion and spreading on immobilized fibrinogen and also prevented fibrin clot retraction. The peptide corresponded to the integrin β_3 C-terminus. Next steps include modifying the peptide for <i>in vivo</i> applications.	Patent application for the RGT peptide filed in China and the U.S.; licensing status undisclosed	Su, X. <i>et al. Blood</i> ; published online April 8, 2008; doi:10.1182/blood-2007-09-110437 Contact: Xiaodong Xi, Shanghai Jiaotong University School of Medicine, Shanghai, China e-mail: xixiaodong@shsmu.edu.cn